The SURVIVE trial of the targeted vaccine SurVaxM did not meet its primary OS end point due to longer-than-expected survival ...

The FDA approved tucatinib with trastuzumab and pertuzumab as maintenance therapy in HER2-positive breast cancer, based on ...

CLL care shifts to targeted combinations, confronting BTK resistance with next-gen inhibitors, degraders, and BCL2 drugs, ...

The addition of carotuximab (ENV-105) to apalutamide (Erleada) significantly improved progression-free survival (PFS) ...

Among 102 patients with recurrent or metastatic head and neck squamous cell carcinoma evaluable for response, Dr Swiecicki reports a confirmed overall response rate (ORR) of 42% by a blinded ...

Five myeloma experts share their top takeaways from IMS 2026, including the CERVINO trial and long-term follow-up from the PERSEUS study. Giada Bianchi, MD, discusses tailoring therapy in myeloma, ...

Otero, MD, discusses findings from the LINKER-SMM1 trial presented at the IMS Annual Meeting. Paula Rodríguez-Otero, MD, consultant and deputy professor at the University of Navarra, Spain, discusses ...

Adding aglatimagene besadenovec (CAN-2409) to external beam radiation therapy (EBRT) was associated with greater lymphocyte infiltration of prostate tissue and greater lymphocyte- ...

Broader community enrollment improves external validity by capturing patients with comorbidities and real-world treatment patterns, while familiarizing clinicians with toxicity management before ...

Firmonertinib is a highly brain-penetrant, mutation-selective EGFR inhibitor with activity against classical and uncommon ...

Komal L. Jhaveri, MD, discusses the unmet need, EMBER-3 data, and future directions after the FDA approved imlunestrant plus ...

In an interview with Targeted OncologyTM, Daniel Heng, MD, of the University of Calgary, discusses the recent FDA approval of belzutifan (Welireg) plus lenvatinib (Lenvima) for patients with advanced ...